A Message from SmallCaps Daily 
NNVC has recently suggested that its revolutionary broad-spectrum antiviral drug NV-387 could have strong potential for the treatment of measles! Whether the economy continues to slide or not, one thing is certain: the world will still need medicine and medical breakthroughs. NanoViricides, Inc. (NYSE: NNVC) is a growing NYSE biotech firm that may be at a value right now as it continues to develop revolutionary broad-spectrum antiviral drugs that viruses cannot escape. Viruses targeted include Covid, RSV, Bird Flu and measles. What’s important to highlight is that NNVC’s business is NOT affected by the tariff policies of the US government or corresponding retaliatory policies of other governments, and it is not affected by the spending cuts being implemented by the current White House administration. This means NNVC is a biotech company that may be an effective hedge against the current general economic turmoil! Why is NNVC standing out? For the company’s development of a drug called NV-387. NV-387 is abroad-spectrum antiviral drug that the company plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. Additionally, the Company has also developed a drug against HIV/AIDS, namely NV-HIV-1. The Company believes NV-HHV-1 in combination with some of the existing drugs could lead to finally achieving cures of HIV infection! In a world that has been forever changed by how quickly a virus can lead to chaos, NNVC is developing antiviral treatments that could be a gamechanger for society while producing shareholder value. Most recently the company acquired the Measles virus and has completed growing the virus in the small quantities required for conducting an animal model study. This means NNVC can now determine how effective NV-387 would be against the Measles virus! Discover how NNVC’s NV-387 is possibly the most advanced drug candidate there is to fight deadly viruses and how it could create shareholder value. | 
0 Response to "NNVC: One Drug. Many Viruses. Massive Market Potential"
Post a Comment